Immedica Pharma US Inc. Announces Accepted Abstracts for Poster Presentation at the AES 2025 Annual Meeting

Chicago, IL, November 25, 2025 – Immedica Pharma US Inc. announced that two abstracts featuring ganaxolone have been accepted for poster presentation at the American Epilepsy Society (AES) 2025 Annual Meeting, taking place December 5–9 in Atlanta, Georgia.

Both posters highlight important ganaxolone data and will be presented during **Poster Session 3**. Details are as follows:

Date: Monday, December 8

Time: 8:00 AM–2:00 PM (Authors present: 12:00–1:45 PM)

Location: Georgia World Congress Center, Poster Hall B3

Poster 1: *A Modified Titration Regimen of Ganaxolone in the Treatment of Rare Seizure Disorders Optimizes Tolerability*

Authors: Kenneth Johnson, Michelle L. Shuffett, Christine Ochoa Escamilla, Joe Hulihan, Rajsekar Rajaraman, Mary Kay Koenig

Poster Number: 3.378

Poster 2: *A Phase I, Single-Dose Study of Ganaxolone Pharmacokinetics in Adult Subjects with Normal and Impaired Hepatic Function*

Authors: Christine Ochoa Escamilla, Joseph Hulihan, Richard Alfred Preston, Thomas C. Marbury

Poster Number: 3.137
All AES 2025 abstracts are available online at the following link: AES Abstracts

About the American Epilepsy Society
Founded in 1936, the American Epilepsy Society (AES) is a medical and scientific society whose members are dedicated to advancing research and education for preventing, treating and curing epilepsy. The AES Annual Meeting brings together healthcare providers, scientists, advocates, industry, and other professionals dedicated to better outcomes for people with epilepsy.

About Immedica Pharma US Inc.
Immedica Pharma US Inc. is an affiliate of Immedica Pharma AB, a pharmaceutical company headquartered in Stockholm, Sweden. Immedica is focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover

marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology and specialty care. Immedica was founded in 2018 and employs today around 160 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo.

For more information visit www.ImmedicaUS.com

Immedica contact
Linda Holmström
VP, Head of HR & Communication
Linda.holmstrom@immed

Immedica Pharma US Inc.
(c/o Portal Innovations)
400 N. Aberdeen, Suite 959
Chicago, Illinois 60642